Silo Pharma Inc. Anticipates Key Study Results for PTSD Treatment SPC-15

Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is nearing a pivotal moment in its quest to address Post-Traumatic Stress Disorder (PTSD) with its lead candidate, SPC-15. The company expects to receive data from two key preclinical studies within the next 30 to 90 days. These studies, which include IND-enabling GLP-compliant toxicology and toxicokinetic testing, along with a large animal safety study requested by the FDA, are critical steps towards submitting an Investigational New Drug (IND) application. Success in these studies could lead to a Phase 1 clinical trial by 2026, utilizing the FDA's 505(b)(2) pathway for expedited development.

The significance of SPC-15 lies in its novel approach to preventing PTSD, a condition that has not seen a new FDA-approved drug in nearly 25 years. As an intranasal prophylactic designed to enhance stress resilience, SPC-15 represents a potential paradigm shift in the treatment of stress-induced psychiatric disorders. The upcoming study results will not only inform the IND application but also shed light on the therapy's safety and efficacy, offering hope to millions affected by PTSD worldwide.

For more information on Silo Pharma's innovative approach to treating PTSD and other CNS diseases, visit https://www.SiloPharma.com.